Predictive Value of Adenoviral Load for Bronchial Mucus Plugs Formation in Children with Adenovirus Pneumonia

Table 1

Comparison of the clinical characteristics of patients with AdV pneumonia in the BMP and control group.

Variables	BMP group (n = 185)	Control group (n = 268)	value
Characteristics
Gender (male)	112 (60.54)	179 (66.79)	0.172
Age (M(P25–P75))/(months)	36 (12–60)	24 (12–42)	0.004
Age group (months)
<6	5 (2.70)	10 (3.73)	0.548
6–23	65 (35.14)	146 (54.48)	<0.001
24–36	37 (20.00)	35 (13.06)	0.047
37–48	24 (12.97)	32 (11.94)	0.743
49–60	21 (11.35)	19 (7.09)	0.116
>60	35 (18.92)	24 (8.96)	0.002
Length of hospitalization (M(P25–P75))/d	10 (8–16)	9 (7–14)	0.005
Allergic constitution (n (%))	18 (9.73)	21 (7.84)	0.480
Signs and symptoms
Dyspnea (n (%))	49 (26.49)	50 (17.48)	0.047
Heat range (x ± s)/(d)	10.52 ± 3.60	8.18 ± 3.16	0.001
Tachycardia (n (%))	119 (64.32)	146 (51.05)	0.037
Lung rales (n (%))	152 (82.16)	232 (86.56)	<0.001
Lung wheezing (n (%))	25 (13.51)	45 (16.79)	0.343
Hepatomegaly (n (%))	53 (28.65)	66 (23.08)	0.339
Poor spirit (n (%))	22 (11.89)	15 (5.60)	0.016
Complication (n (%))	70 (37.84)	75 (26.22)	0.027
Disease severity
Mild (n (%))	101 (54.59)	188 (70.15)	0.001
Severe (n (%))	84 (45.40)	80 (29.85)	0.001
Admission to PICU (n (%))	44 (23.78)	31 (11.57)	0.001
Ventilator-assisted ventilation (n (%))	50 (27.03)	50 (18.66)	0.035
Bronchiolitis obliterans (n (%))	23 (12.43)	9 (3.36)	<0.001
Laboratory characteristics
WBC (M(P25–P75))/×109 L−1	7.03 (4.56–9.38)	7.34 (5.45–10.55)	0.156
N% (M(P25–P75))/%	49.70 (41.35–66.6)	48.9 (34.1–61.3)	0.103
Hb (M(P25–P75))/g·L−1	109 (98.5–118)	110 (101–119)	0.173
PLT (M(P25–P75))/×109 L−1	276 (172.5–383.5)	281 (202–399)	0.568
CRP (M(P25–P75))/mg·L−1	9.28 (3.13–26.37)	7.38 (3.13–20.37)	0.01
LDH (M(P25–P75))/U·L−1	463 (349–634)	406 (325–552)	0.003
DD (M(P25–P75))/mg·L−1	1.43 (0.62–3.20)	0.73 (0.41–1.7)	0.001
CK-MB (M(P25–P75))/ng·mL−1	29 (23–40.25)	28 (21–41)	0.440
ALT (M(P25–P75))/U·L−1	21.4 (14.8–33.46)	18.1 (12–34.75)	0.583
Mixed infection (n (%))	121 (65.41)	144 (53.73)	0.015
Bacterial coinfection (n (%))	29 (15.68)	47 (16.43)	0.602
Mycoplasma coinfection (n (%))	101 (54.59)	93 (32.52)	<0.001
AdV load from BALF (x ± s), log10 copies/mL	6.47 ± 2.02	5.49 ± 1.98	<0.001
Humoral immunity (M(P25–P75), %)
IgG (M(P25–P75))/g·L−1	8.72 (6.96–10.90)	8.02 (6.36–9.72)	0.214
IgA (M(P25–P75))/g·L−1	0.73 (0.44–1.22)	0.96 (0.7–1.36)	0.026
IgM (M(P25–P75))/g·L−1	1.06 (0.69–1.42)	0.98 (0.71–1.38)	0.535
Cellular immunity (M(P25–P75), %)
CD3+	55.63 (45.3–63.13)	56.67 (46.55–65.89)	0.562
CD3+CD4+	26.86 (18.98–32.83)	27 (21.93–36.18)	0.936
CD3+CD8+	21.98 (17.55–29.35)	20.28 (17.36–28.02)	0.737
Radiological characteristics
Lung consolidation (n (%))	95 (51.35)	105 (36.71)	0.01
Pleural effusion (n (%))	11 (5.95)	5 (1.75)	0.021
Treat time (M(P25–P75))/day of course
Corticosteroids	9 (7–11)	8 (6–10)	0.673
Gamma globulin	8 (5–9)	7 (4–9)	0.904
Tracheoscopy intervention	10 (6–14)	9 (5–14)	0.131

BMP, bronchial mucus plug; AdV, Adenovirus; WBC, leukocyte; N%, percentage of neutrophils; Hb, hemoglobin; PLT, platelet; CRP, C-reactive protein; LDH, lactate dehydrogenase; DD, D-dimer; CK-MB, creatine kinase isoenzyme; ALT, gluten laboratory data of alanine transaminase; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M.